Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assay

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Teeranaipong, Phairote ^a,e   Hosoya, Noriaki ^a   Kawana Tachikawa, Ai ^a   Fujii, Takeshi ^a,f   Koibuchi, Tomohiko ^a   Nakamura, Hitomi ^a   Koga, Michiko ^a   Kondo, Naoyuki ^a,b   Gao, George F ^c   Hoshino, Hiroo ^d   Matsuda, Zene ^a,b   Iwamoto, Aikichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE OF BIOPHYSICS   (China)

^c INSTITUTE OF MICROBIOLOGY   (China)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemokine receptor; Co receptor; Co receptor usage; Fusion; HIV 1; Tropism

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GREEN FLUORESCENT PROTEIN; MARAVIROC; PLERIXAFOR; RENILLA LUCIFERIN 2 MONOOXYGENASE;

ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ASSAY; CELL CLONING; CELL FUSION; COCULTURE; CONTROLLED STUDY; ENVELOPE GENE; EXPRESSION VECTOR; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTERNAL RIBOSOME ENTRY SITE; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RAPID PHENOTYPIC TROPISM ASSAY; TURNAROUND TIME; VIRAL TROPISM; VIRUS ENVELOPE; VIRUS LOAD; VIRUS STRAIN;

CHEMOKINE RECEPTOR; CO-RECEPTOR; CO-RECEPTOR USAGE; FUSION; HIV-1; TROPISM;

ANTIGENS, CD4; CELL FUSION; CELL LINE; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HIV INFECTIONS; HIV-1; HUMANS; LUCIFERASES; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; VIRAL TROPISM; VIROLOGY;

EID: 84891532792     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18723     Document Type: Article

References (25)

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49(11):4721-32.
2. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al. A new classification for HIV-1. Nature. 1998;391(6664):240.
3. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 2004;20(1):111-26.
4. Iwamoto A, Hosoya N, Kawana-Tachikawa A. HIV-1 tropism. Protein Cell. 2010;1(6):510-3.
5. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008;359(14):1442-55.
6. Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, Sullivan J, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009;199(11):1638-47.
7. Shioda T, Levy JA, Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 1991;349(6305):167-9.
8. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science. 1991;253(5015):71-4.
9. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokinemediated blockade of infection. Nat Med. 1996;2(11):1244-7.
10. Hoffman TL, Doms RW. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol. 1999;16(1):57-65.
11. Harrigan PR, Geretti AM. Genotypic tropism testing: evidence-based or leap of faith? AIDS. 2011;25(2):257-64.
12. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 2011;11(5):394-407.
13. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51(2):566-75.
14. Wang J, Kondo N, Long Y, Iwamoto A, Matsuda Z. Monitoring of HIV-1 envelope-mediated membrane fusion using modified split green fluorescent proteins. J Virol Methods. 2009;161(2):216-22.
15. Kondo N, Miyauchi K, Meng F, Iwamoto A, Matsuda Z. Conformational changes of the HIV-1 envelope protein during membrane fusion are inhibited by the replacement of its membrane-spanning domain. J Biol Chem. 2010;285(19):14681-8.
16. Soda Y, Shimizu N, Jinno A, Liu HY, Kanbe K, Kitamura T, et al. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun. 1999;258(2):313-21.
17. Shimizu N, Tanaka A, Oue A, Mori T, Ohtsuki T, Apichartpiyakul C, et al. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS. 2009;23(7):761-9.
18. Murray EJ, Leaman DP, Pawa N, Perkins H, Pickford C, Perros M, et al. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J Virol. 2010;84(14):7288-99.
19. Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, et al. Maraviroc and other HIV-1 entry inhibitors exhibit a classspecific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother. 2012;56(8):4154-60.
20. Chang CH, Hinkula J, Loo M, Falkeborn T, Li R, Cardillo TM, et al. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. PloS One. 2012;7(7):e41235.
21. Vila-Coro AJ, Mellado M, Martin de Ana A, Lucas P, del Real G, Martinez AC, et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci U S A. 2000;97(7):3388-93.
22. Badr G, Borhis G, Treton D, Moog C, Garraud O, Richard Y. HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL)20, and CCL21. J Immunol. 2005;175(1):302-10.
23. Lin NH, Negusse DM, Beroukhim R, Giguel F, Lockman S, Essex M, et al. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods. 2010;169(1):39-46.
24. Zhu P, Liu J, Bess J, Jr., Chertova E, Lifson JD, Grise H, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006;441(7095):847-52.
25. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. Coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry. 2009;3(3):94-102.